

An NA-deficient 2009 pandemic H1N1 influenza virus mutant can efficiently replicate in cultured cells

Emi Inoue · Masahiro Ieko · Nobuhiko Takahashi ·
Yoshiaki Osawa · Katsunori Okazaki

Received: 27 August 2013 / Accepted: 6 October 2013 / Published online: 19 October 2013
© Springer-Verlag Wien 2013

Abstract We identified a novel neuraminidase (NA)-deficient virus that was a 2009 pandemic influenza H1N1 virus mutant. The mutant virus had a deletion of 1,009 nt in the NA gene and lacked an enzymatic domain. Although the yield of the NA-deficient virus was limited, it formed large plaques when applied to MDCK cell cultures, indicating that the virus was able to spread to adjacent cells. Furthermore, the NA-deficient virus was eluted from chicken erythrocytes at 37 °C, even in the presence of the antiviral drug peramivir. Spread of this NA-deficient virus may pose a potential threat to anti-influenza therapies.

Influenza A viruses commonly infect a large variety of hosts, including humans, pigs, horses and birds. Two of the eight RNA segments of the genome encode the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), which have 16 and 9 subtypes, respectively [2]. The HA protein is involved in virus attachment to cell-surface receptors and mediates entry of the virus into the cell by membrane fusion. The NA protein is required to release progeny virions and to prevent them from aggregating. This enzyme removes terminal sialic acids from oligosaccharide side chains, where HA binds [3].

The pandemic influenza A (H1N1) virus [A(H1N1)pdm09], containing a combination of swine, avian and human virus gene segments, emerged in humans in Mexico City in March 2009 and quickly spread worldwide [1, 17]. To date, only a small number of oseltamivir-resistant A(H1N1)pdm09 strains containing a single amino acid change (His to Tyr) at position 275 within NA (H275Y) have been detected [13] and reported among seasonal H1N1 viruses worldwide since the 2007–2008 influenza season [20]. In Japan, a surveillance study conducted during the 2008–2009 influenza season showed that oseltamivir resistance was evident in 99.7 % of H1N1 virus isolates [18].

We previously showed that the HA genes of 70 A(H1N1)pdm09 strains isolated from a single student population in 2009 in Tobetsu, Hokkaido, clustered into three groups [7]. Of these isolates, two strains exhibited lower sensitivity to oseltamivir than other strains. Morlighem et al. conducted a phylogenetic analysis of 253 samples based on the NA gene of Japanese A(H1N1)pdm09. They identified an N248D mutation in NA, which allowed discrimination of isolates between the early (May 2009) and peak (October 2009 to January 2010) phases of infection [13]. In the present study, we describe for the first time the isolation of an NA-deficient mutant of A(H1N1)pdm09, and its subsequent characterization.

One of the two isolates with low sensitivity to oseltamivir, A/Hokkaido/T64/2009 (H1N1) (T64), was found to form plaques of various sizes on Madin-Darby canine kidney (MDCK) cells, indicating that it was composed of a mixed population of virions. We analyzed several plaques and successfully obtained an NA-deficient mutant, designated T64LP4, which formed large uniform-sized plaques (Fig. 1A). A full-genome amplification technique [8] demonstrated that T64LP4 lacked the NA gene (Fig. 1B).

E. Inoue · Y. Osawa · K. Okazaki (✉)
Department of Microbiology and Immunology, Faculty of
Pharmaceutical Sciences, Health Sciences University of
Hokkaido, Ishikari-Tobetsu, Hokkaido 061-0293, Japan
e-mail: kokazaki@hoku-iryo-u.ac.jp

M. Ieko · N. Takahashi
Department of Internal Medicine, Faculty of Dentistry, Health
Sciences University of Hokkaido, Ishikari-Tobetsu,
Hokkaido 061-0293, Japan




Fig. 1 Characterization of the T64 parental strain and T64LP4 mutant strain. **(A)** Plaque morphology of T64 and T64LP4 strains on MDCK cells. Virus was inoculated onto MDCK cells grown in 6-well plates and incubated at 37 °C for 1 h. Cells were then overlaid with Dulbecco's modified Eagle's medium (DMEM) supplemented with 1 % Avicel RC-591 (FMC BioPolymer), 50 µg/mL gentamicin, and 5 µg/mL trypsin and incubated at 35 °C. Crystal violet staining was used to visualize plaques at 2 days postinfection. **(B)** Amplification of the T64 and T64LP4 genomes. Each segment of the virus was

amplified as described previously [8]. A 2-Log DNA ladder was used as a molecular weight marker. Arrowheads indicate bands corresponding to the HA and NA genes. **(C)** Schematic diagram of NA proteins and the 0.5-kb fragment. The 1.5-kb fragment derived from T64 and the 0.5-kb fragment from T64LP4 were sequenced directly using primers specific for the NA gene. Amino acid differences among Sapporo, T64, and T64LP4 strains are indicated. The transmembrane and enzymatic domains are indicated in gray and by hatched boxes, respectively

The amplification products included a prominent extra band that migrated faster than that of the NS gene. The nucleotide sequence of the 0.5-kb band coincided with 166 nt at the 5'-terminus and 235 nt at the 3'-terminus of the NA gene for the parental strain T64 (DDBJ Accession Nos. AB847956 and AB847955). Phylogenetic analysis of the gene indicated that T64LP4 was derived from the parental virus (data not shown). The 1,009-nt deletion generated an open reading frame (ORF) encoding a protein of 57 amino acids (aa), with 55 aa corresponding to the N-terminus of NA (Fig. 1C). The mutant NA comprised the transmembrane and 20-aa stalk regions, along with an additional 2 aa (Leu and Ser). The mutant NA lacked an enzymatic globular head domain. We also observed two aa changes in the mutant T64 NA (D199N and D416N), based on A/Sapporo/1/2009 (H1N1) (Sapporo), which was the first A(H1N1)pdm09 isolated in Hokkaido.

Growth kinetics in MDCK cells were compared between the parent T64 and mutant T64LP4 strains. The growth rate of T64LP4 was slower than that for T64 (Fig. 2), and the yield of T64LP4 was 1,000-fold lower than that of T64 at 32 h postinfection. After 32 h postinfection, *Clostridium perfringens* sialidase was added to the culture medium of T64- and T64LP4-infected cells. Although the enzyme had no effect on T64 titer, the T64LP4 titer increased more than 40-fold 2 h after sialidase was added. This finding indicated that the low yield of T64LP4 was partially due to a lack of NA activity.

Elution of T64 and T64LP4 virions from chicken erythrocytes was compared. Both types were eluted from erythrocytes after a 6-h incubation at 37 °C, although T64LP4 lacked the NA enzymatic domain (Fig. 3). Peramivir inhibited elution of T64 and A/Denmark/524/2009 (H1N1) (Den/524). No inhibition was observed for T64LP4




Fig. 2 One-step growth of T64 and T64LP4 viruses in MDCK cells. Monolayers of MDCK cells were infected at a multiplicity of infection of approximately 6 PFU/cell and incubated at 35 °C. At 32 h postinfection, *C. perfringens* sialidase (New England Biolabs) was added to a final concentration of 30 mU/mL. At the indicated time points, supernatants were harvested, and virus titers were determined using plaque assays




Fig. 3 Virus elution assays for T64 and T64LP4 using chicken erythrocytes. Hemagglutination titers of the viruses were determined on ice using the microtiter method [21]. Peramivir (Shionogi) was added to each well at a final concentration of 100 nM. Microtiter plates were incubated at 37 °C for 1 h, and titers were determined at 1-h intervals. Open and solid symbols indicate virus alone and virus with peramivir, respectively

or A/Denmark/527/2009 (H1N1) (Den/H275Y), which contained the H275Y mutation.

An optimal balance between receptor binding and receptor destruction by HA and NA respectively, is important for viral replication in cultured cells and experimental

animals [5, 11, 15, 16, 19, 24]. Mismatched pairs of HA and NA can be rescued by adaptive mutations in one or both proteins after several cycles of infection in cell culture [4, 9, 10]. Oseltamivir-resistant viruses with the H275Y mutation exhibited decreased ratios of NA:HA activities compared with drug-sensitive viruses [23]. For T64 and T64LP4, two aa substitutions (K153E and M257I) were observed in HA (DDBJ accession Nos. AB665976 and AB847957). At positions 153-157, there is a prominent loop to the left of the receptor-binding site [22]. Substitution from a positively charged Lys to a negatively charged Glu affects the affinity for the negatively charged sialic acid moiety. It is therefore possible that T64LP4 has reduced receptor-binding affinity, thereby enabling it to be eluted from erythrocytes despite the fact that it lacks NA.

Peramivir treatment resulted in no observable effects on the growth of T64LP4- or Den/H275Y (data not shown). The S247N mutation of NA resulted in a moderate reduction to oseltamivir and zanamivir sensitivity, as has also been observed in A(H1N1)pdm09 isolates [6]. When the H275Y mutation is combined with the S247N mutation, the virus becomes highly resistant to oseltamivir. Although the yield of T64LP4 was decreased by approximately 1,000-fold compared with the parental strain, it formed large plaques on MDCK cells. This finding indicates that NA is not essential for cell-to-cell infection. Mori et al. reported that influenza viruses can spread in an NA-independent manner to adjacent cells [12]. Furthermore, bacterial sialidase can improve the yield of T64LP4. Upper respiratory tract bacteria such as *Streptococcus pneumoniae* release sialidase, and even human saliva contains sialidase [14]. It is therefore postulated that T64LP4 can efficiently replicate in the upper respiratory tract of humans. Such an NA-deficient influenza virus will more than likely be resistant to all NA inhibitors and pose a potential threat to anti-influenza therapies. To control influenza epidemics, surveillance and extensive studies on NA-deficient clinical isolates are urgently required.

Acknowledgments This work was supported in part by a grant from the Ministry of Health, Labour and Welfare of Japan. We thank Dr. Odagiri of the National Institute of Infectious Diseases, Japan, for providing A/Denmark/524/2009 (H1N1) and A/Denmark/527/2009 (H1N1).

References

- Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. *N Engl J Med* 360:2605–2615
- Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B, Osterhaus AD (2005) Characterization of a novel influenza A virus hemagglutinin

- subtype (H16) obtained from black-headed gulls. *J Virol* 79:2814–2822
3. Gamblin SJ, Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. *J Biol Chem* 285:28403–28409
 4. Hughes MT, Matrosovich M, Rodgers ME, McGregor M, Kawaoka Y (2000) Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice. *J Virol* 74:5206–5212
 5. Hughes MT, McGregor M, Suzuki T, Suzuki Y, Kawaoka Y (2001) Adaptation of influenza A viruses to cells expressing low levels of sialic acid leads to loss of neuraminidase activity. *J Virol* 75:3766–3770
 6. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, Speers D, Kelso A, Lin RT, Maurer-Stroh S, Barr IG (2011) Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. *Euro Surveill* 16 pii: 19884
 7. Inoue E, Ieko M, Takahashi N, Osawa Y, Okazaki K (2012) Phylogenetic analyses of pandemic influenza A (H1N1) virus in university students at Tobetsu, Hokkaido, Japan. *Microbiol Immunol* 56:273–279
 8. Inoue E, Wang X, Osawa Y, Okazaki K (2010) Full genomic amplification and subtyping of influenza A virus using a single set of universal primers. *Microbiol Immunol* 54:129–134
 9. Kaverin NV, Gambaryan AS, Bovin NV, Rudneva IA, Shilov AA, Khodova OM, Varich NL, Sinitsin BV, Makarova NV, Kropotkina EA (1998) Post-reassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match. *Virology* 244:315–321
 10. Kaverin NV, Matrosovich MN, Gambaryan AS, Rudneva IA, Shilov AA, Varich NL, Makarova NV, Kropotkina EA, Sinitsin BV (2000) Intergenic HA-NA interactions in influenza A virus: post-reassortment substitutions of charged amino acid in the hemagglutinin of different subtypes. *Virus Res* 66:123–129
 11. Mitnaul LJ, Matrosovich M, Castrucci MR, Tuzikov AB, Bovin NV, Kobasa D, Kawaoka Y (2000) Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. *J Virol* 74:6015–6020
 12. Mori K, Haruyama T, Nagata K (2011) Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses. *PLoS One* 6:e28178
 13. Morlighem JÉ, Aoki S, Kishima M, Hanami M, Ogawa C, Jalloh A, Takahashi Y, Kawai Y, Saga S, Hayashi E, Ban T, Izumi S, Wada A, Mano M, Fukunaga M, Kijima Y, Shiomi M, Inoue K, Hata T, Koretsune Y, Kudo K, Himeno Y, Hirai A, Takahashi K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kawaoka Y, Hayashizaki Y, Ishikawa T (2011) Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic. *PLoS One* 6:e18956
 14. Nishikawa T, Shimizu K, Tanaka T, Kuroda K, Takayama T, Yamamoto T, Hanada N, Hamada Y (2012) Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor. *PLoS One* 7:e45371
 15. Rudneva IA, Kovaleva VP, Varich NL, Farashyan VR, Gubareva LV, Yamnikova SS, Popova IA, Presnova VP, Kaverin NV (1993) Influenza A virus reassortants with surface glycoprotein genes of the avian parent viruses: effects of HA and NA gene combinations on virus aggregation. *Arch Virol* 133:437–450
 16. Rudneva IA, Sklyanskaya EI, Barulina OS, Yamnikova SS, Kovaleva VP, Tsvetkova IV, Kaverin NV (1996) Phenotypic expression of HA-NA combinations in human-avian influenza A virus reassortants. *Arch Virol* 141:1091–1099
 17. Schnitzler SU, Schnitzler P (2009) An update on swine-origin influenza virus A/H1N1: a review. *Virus Genes* 39:279–292
 18. Ujike M, Shimabukuro K, Mochizuki K, Obuchi M, Kageyama T, Shirakura M, Kishida N, Yamashita K, Horikawa H, Kato Y, Fujita N, Tashiro M, Odagiri T, Working Group for Influenza Virus Surveillance in Japan (2010) Oseltamivir-resistant influenza viruses A (H1N1) during 2007–2009 influenza seasons, Japan. *Emerg Infect Dis* 16:926–935
 19. Wagner R, Matrosovich M, Klenk HD (2002) Functional balance between haemagglutinin and neuraminidase in influenza virus infections. *Rev Med Virol* 12:159–166
 20. World Health Organization (2008) Influenza A(H1N1) virus resistance to oseltamivir. http://www.who.int/influenza/patient_care/antivirals/oseltamivir_summary/en/
 21. World Health Organization (2011) Manual for the laboratory diagnosis and virological surveillance of influenza
 22. Yang H, Carney P, Stevens J (2010) Structure and Receptor binding properties of a pandemic H1N1 virus hemagglutinin. *PLoS Curr* 2:RRN1152
 23. Yang JR, Huang YP, Chang FY, Hsu LC, Huang HY, Pan YT, Lin YC, Wu HS, Liu MT (2013) Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009–2011. *J Med Virol* 85:379–387
 24. Yen HL, Liang CH, Wu CY, Forrest HL, Ferguson A, Choy KT, Jones J, Wong DD, Cheung PP, Hsu CH, Li OT, Yuen KM, Chan RW, Poon LL, Chan MC, Nicholls JM, Krauss S, Wong CH, Guan Y, Webster RG, Webby RJ, Peiris M (2011) Hemagglutinin-neuraminidase balance confers respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in ferrets. *Proc Natl Acad Sci USA* 108:14264–14269